RxDoctor Payments Data

William Knopf, MD

Cardiovascular Disease · Macon, GANPI 1922007541

Payments from drug & device makers

$42,515in general payments, 2019–2025

Across 122 payments — averaging $348.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Semler Scientific, Inc.$40K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$774
  • Novartis$300
  • Abbott$163
  • Shockwave Medical, Inc$150
  • Boston Scientific$125
  • plus $1K from 22 others

What the payments were for

  • Consulting fees$40,00094%
  • Food & beverage$2,5156%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,515 in reported general payments places this provider in the 90th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$1,420,665
Medicare patients
2,294
Services billed
20,942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,190$1,076,119
EntrestoSacubitril/Valsartan584$548,517
BrilintaTicagrelor278$177,959
XareltoRivaroxaban168$148,553
Repatha SureclickEvolocumab197$130,027
FarxigaDapagliflozin Propanediol78$49,641
MounjaroTirzepatide31$32,406
WegovySemaglutide13$16,964
Repatha SyringeEvolocumab16$12,946
Praluent PenAlirocumab12$12,297
Metoprolol Succinate1,026$10,510
Flecainide Acetate248$8,498
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide335$7,669
Atorvastatin Calcium906$7,379
ClopidogrelClopidogrel Bisulfate648$6,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$1,076,1191,190 claims
NovartisEntresto$300$548,517584 claims
AstraZenecaBrilinta, Farxiga$124$227,600356 claims
Johnson & JohnsonXarelto$66$148,553168 claims
Novo NordiskWegovy$23$16,96413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →